{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:51:36Z","timestamp":1788961896471,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11060-026-05491-w","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:51:28Z","timestamp":1772470288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy"],"prefix":"10.1007","volume":"177","author":[{"given":"Irem","family":"Yenidogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Tabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"9","key":"5491_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov 8(9):1069\u20131086","journal-title":"Cancer Discov"},{"key":"5491_CR2","doi-asserted-by":"crossref","unstructured":"Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, et al (2023) Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 133(2)","DOI":"10.1172\/JCI163447"},{"issue":"1","key":"5491_CR3","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1038\/s41467-024-49595-1","volume":"15","author":"AB Levine","year":"2024","unstructured":"Levine AB, Nobre L, Das A, Milos S, Bianchi V, Johnson M et al (2024) Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Nat Commun 15(1):5790","journal-title":"Nat Commun"},{"issue":"5","key":"5491_CR4","first-page":"1042","volume":"171","author":"BB Campbell","year":"2017","unstructured":"Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R et al (2017) Compr Anal Hypermutation Hum Cancer Cell 171(5):1042\u201356e10","journal-title":"Compr Anal Hypermutation Hum Cancer Cell"},{"key":"5491_CR5","doi-asserted-by":"crossref","unstructured":"Budhiraja S, Najem H, Tripathi S, Wadhawani NR, Horbinski C, McCord M, et al (2023) Immunobiology and cytokine modulation of the pediatric brain tumor microenvironment: a scoping review. Cancers (Basel). 15(14)","DOI":"10.3390\/cancers15143655"},{"issue":"1","key":"5491_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11060-020-03578-6","volume":"149","author":"C Cacciotti","year":"2020","unstructured":"Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C et al (2020) Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience. J Neurooncol 149(1):113\u2013122","journal-title":"J Neurooncol"},{"issue":"4","key":"5491_CR7","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1097\/MPH.0000000000001339","volume":"41","author":"HS Gorsi","year":"2019","unstructured":"Gorsi HS, Malicki DM, Barsan V, Tumblin M, Yeh-Nayre L, Milburn M et al (2019) Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience. J Pediatr Hematol Oncol 41(4):e235\u2013e41","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"5491_CR8","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/neuonc\/noad031","volume":"25","author":"IJ Dunkel","year":"2023","unstructured":"Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, Andr\u00e9 N et al (2023) Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol 25(8):1530\u20131545","journal-title":"Neuro Oncol"},{"issue":"1","key":"5491_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11060-025-05241-4","volume":"176","author":"B Gulsuna","year":"2025","unstructured":"Gulsuna B, Lopez R, Kemp RDW, Yurtluk MD, Erkan B, \u00d6zaydin B et al (2025) The current status of immune checkpoint inhibitors in pediatric CNS tumors: a systematic review with a representative case of CMMRD-associated glioma. J Neurooncol 176(1):63","journal-title":"J Neurooncol"},{"issue":"23","key":"5491_CR10","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","volume":"29","author":"A Das","year":"2023","unstructured":"Das A, Tabori U, Sambira Nahum LC, Collins NB, Deyell R, Dvir R et al (2023) Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency. Clin Cancer Res 29(23):4770\u20134783","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5491_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri1457","volume":"4","author":"AL Mellor","year":"2004","unstructured":"Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4(10):762\u2013774","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"5491_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/vaccines3030703","volume":"3","author":"JC Mbongue","year":"2015","unstructured":"Mbongue JC, Nicholas DA, Torrez TW, Kim NS, Firek AF, Langridge WH (2015) The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity. Vaccines (Basel) 3(3):703\u2013729","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"5491_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/neuonc\/noad174","volume":"26","author":"TS Johnson","year":"2024","unstructured":"Johnson TS, MacDonald TJ, Pacholczyk R, Aguilera D, Al-Basheer A, Bajaj M et al (2024) Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. Neuro Oncol 26(2):348\u2013361","journal-title":"Neuro Oncol"},{"issue":"1","key":"5491_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1470-2045(24)00640-5","volume":"26","author":"L Negm","year":"2025","unstructured":"Negm L, Chung J, Nobre L, Bennett J, Fernandez NR, Nunes NM et al (2025) The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study. Lancet Oncol 26(1):123\u2013135","journal-title":"Lancet Oncol"},{"issue":"8","key":"5491_CR15","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00381-021-05229-1","volume":"37","author":"S Alphones","year":"2021","unstructured":"Alphones S, Chatterjee U, Singh A, Das A, Zameer L, Achari R et al (2021) Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas - institutional experience and review of literature. Childs Nerv Syst 37(8):2521\u20132530","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"5491_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/ijc.29724","volume":"138","author":"N Amayiri","year":"2016","unstructured":"Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C et al (2016) High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138(2):380\u2013385","journal-title":"Int J Cancer"},{"issue":"1","key":"5491_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","volume":"28","author":"A Das","year":"2022","unstructured":"Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC et al (2022) Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med 28(1):125\u2013135","journal-title":"Nat Med"},{"issue":"2","key":"5491_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","volume":"14","author":"A Das","year":"2024","unstructured":"Das A, Fernandez NR, Levine A, Bianchi V, Stengs LK, Chung J et al (2024) Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium. Cancer Discov 14(2):258\u2013273","journal-title":"Cancer Discov"},{"issue":"1","key":"5491_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41588-025-02420-x","volume":"58","author":"NR Fernandez","year":"2026","unstructured":"Fernandez NR, Chang Y, Nunes NM, Dimayacyac JR, Levine A, Ringel A et al (2026) Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma. Nat Genet 58(1):132\u2013142","journal-title":"Nat Genet"},{"issue":"Suppl 4","key":"5491_CR20","first-page":"0","volume":"26","author":"A Das","year":"2024","unstructured":"Das A, Crump O, Kos O, Stengs L, Li A, Levine A et al (2024) Immu-07. combined PD1 and LAG3 inhibition in preclinical models and patients with DNA replication repair deficient glioblastoma (RRD-GBM): an irrdc study. Neuro Oncol 26(Suppl 4):0","journal-title":"Neuro Oncol"},{"issue":"Suppl 4","key":"5491_CR21","first-page":"0","volume":"26","author":"A Das","year":"2024","unstructured":"Das A, Fernandez NR, Bielamowicz KJ, Abebe-Campino G, Caspi S, Per N et al (2024) HGG-11. Trans-species study of idh-mutant replication-repair deficient high-grade gliomas (RRD-HGG) and response to combined targeted and immunotherapy: an irrdc study. Neuro Oncol 26(Suppl 4):0","journal-title":"Neuro Oncol"},{"issue":"5","key":"5491_CR22","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.3390\/curroncol30050379","volume":"30","author":"B Yao","year":"2023","unstructured":"Yao B, Delaidelli A, Vogel H, Sorensen PH (2023) Pediatric Brain Tumours: Lessons from the Immune Microenvironment. Curr Oncol 30(5):5024\u20135046","journal-title":"Curr Oncol"},{"issue":"11","key":"5491_CR23","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","volume":"41","author":"I Ausejo-Mauleon","year":"2023","unstructured":"Ausejo-Mauleon I, Labiano S, de la Nava D, Laspidea V, Zalacain M, Marrod\u00e1n L et al (2023) TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell 41(11):1911\u201326e8","journal-title":"Cancer Cell"},{"key":"5491_CR24","doi-asserted-by":"crossref","unstructured":"Ausejo-Mauleon I, Martinez-Velez N, Lacalle A, de la Nava D, Cebollero J, Villanueva H, et al (2024) Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models. JCI Insight. 9(18)","DOI":"10.1172\/jci.insight.175257"},{"issue":"1","key":"5491_CR25","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1038\/s41467-024-52096-w","volume":"15","author":"AF Andrade","year":"2024","unstructured":"Andrade AF, Annett A, Karimi E, Topouza DG, Rezanejad M, Liu Y et al (2024) Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function. Nat Commun 15(1):7769","journal-title":"Nat Commun"},{"key":"5491_CR26","doi-asserted-by":"crossref","unstructured":"Monnikhof M, Schakelaar MY, Meulenbroeks C, Quist M, Perzolli A, Selten A, et al (2025) Dual targeting of CD155\/TIGIT and PD-L1\/PD-1 immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma. Neuro-Oncology Adv. 7(1)","DOI":"10.1093\/noajnl\/vdaf099"},{"issue":"1","key":"5491_CR27","doi-asserted-by":"publisher","first-page":"e30757","DOI":"10.1002\/pbc.30757","volume":"71","author":"J Krugman","year":"2024","unstructured":"Krugman J, Patel K, Cantor A, Snuderl M, Cooper B, Zan E et al (2024) Pediatric glioblastoma in the setting of constitutional mismatch-repair deficiency treated with upfront lomustine and nivolumab. Pediatr Blood Cancer 71(1):e30757","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"5491_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-019-0804-8","volume":"12","author":"L Yang","year":"2019","unstructured":"Yang L, Li A, Lei Q, Zhang Y (2019) Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. J Hematol Oncol 12(1):125","journal-title":"J Hematol Oncol"},{"issue":"33","key":"5491_CR29","doi-asserted-by":"publisher","first-page":"E3458","DOI":"10.1073\/pnas.1412489111","volume":"111","author":"D Gate","year":"2014","unstructured":"Gate D, Danielpour M, Rodriguez J Jr., Kim GB, Levy R, Bannykh S et al (2014) T-cell TGF-\u03b2 signaling abrogation restricts medulloblastoma progression. Proc Natl Acad Sci U S A 111(33):E3458\u2013E3466","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"5491_CR30","first-page":"490","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard A (2025) PD1 \u00d7 VEGF blocking bispecifics for cancer draw big backing. Nat Rev Drug Discov 24(7):490","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"5491_CR31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/14712598.2025.2557625","volume":"25","author":"R Balsano","year":"2025","unstructured":"Balsano R, Pino M, Bocchero E, Valenzi E, Pressiani T, Bozzarelli S et al (2025) Combining VEGF and PD-1\/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions. Expert Opin Biol Ther 25(9):989\u20131006","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"5491_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"B Chiappinelli Katherine","year":"2015","unstructured":"Chiappinelli Katherine B, Strissel Pamela L, Desrichard A, Li H, Henke C, Akman B et al (2015) Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 162(5):974\u2013986","journal-title":"Cell"},{"issue":"51","key":"5491_CR33","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ et al (2017) Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A 114(51):E10981\u2013e90","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5491_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB (2020) The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol 17(2):75\u201390","journal-title":"Nat Rev Clin Oncol"},{"key":"5491_CR35","doi-asserted-by":"crossref","unstructured":"Taylor BC, Balko JM (2022) Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. Volume 13\u20132022","DOI":"10.3389\/fimmu.2022.844866"},{"key":"5491_CR36","doi-asserted-by":"crossref","unstructured":"Mishra DK, Morris SM, Popovski D, Girard EJ, Bondoc A, Senthil Kumar S, et al (2025) Preclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergy. Neuro-Oncology Advances","DOI":"10.1093\/noajnl\/vdaf241"},{"issue":"3","key":"5491_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477\u2013486","journal-title":"Nat Med"},{"issue":"1","key":"5491_CR38","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","volume":"15","author":"JR McFaline-Figueroa","year":"2024","unstructured":"McFaline-Figueroa JR, Sun L, Youssef GC, Huang R, Li G, Kim J et al (2024) Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat Commun 15(1):10757","journal-title":"Nat Commun"},{"issue":"5","key":"5491_CR39","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","volume":"31","author":"GV Long","year":"2025","unstructured":"Long GV, Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA et al (2025) Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med 31(5):1557\u20131566","journal-title":"Nat Med"},{"key":"5491_CR40","doi-asserted-by":"crossref","unstructured":"She P, Ao X, Zhan X, Zhou W, Cheng Y, Yang J, et al (2024) Breaking through the blood-brain barrier for different kinds of drugs: challenges, solutions, and perspectives. BME Horizon. 2","DOI":"10.70401\/bmeh.2024.124"},{"key":"5491_CR41","doi-asserted-by":"crossref","unstructured":"He Q, Liu J, Liang J, Liu X, Li W, Liu Z et al (2018) Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective. Cells 7(4)","DOI":"10.3390\/cells7040024"},{"key":"5491_CR42","doi-asserted-by":"crossref","unstructured":"Gao Q, Song D, Xu D, Chai X, Ge M (2025) Characteristics of the blood\u2013brain barrier in pediatric brain tumors. Front Pead. Volume 13\u20132025","DOI":"10.3389\/fped.2025.1646641"},{"key":"5491_CR43","doi-asserted-by":"publisher","first-page":"115657","DOI":"10.1016\/j.addr.2025.115657","volume":"224","author":"SJ Parvar","year":"2025","unstructured":"Parvar SJ, Wong CI, Lewis A, Szychot E, Morris CJ, Shorthouse D et al (2025) Convection-enhanced delivery for brain malignancies: Technical parameters, formulation strategies and clinical perspectives. Adv Drug Deliv Rev 224:115657","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"5491_CR44","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12967-024-05096-9","volume":"22","author":"M Tazhibi","year":"2024","unstructured":"Tazhibi M, McQuillan N, Wei H-J, Gallitto M, Bendau E, Webster Carrion A et al (2024) Focused ultrasound-mediated blood\u2013brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma. J Translational Med 22(1):320","journal-title":"J Translational Med"},{"issue":"4","key":"5491_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/ph18040525","volume":"18","author":"S Filieri","year":"2025","unstructured":"Filieri S, Miciaccia M, Armenise D, Baldelli OM, Liturri A, Ferorelli S et al (2025) Can focused ultrasound overcome the failure of chemotherapy in treating pediatric diffuse intrinsic pontine glioma due to a blood\u2013brain. barrier obstacle? Pharmaceuticals 18(4):525","journal-title":"Barrier Obstacle? Pharmaceuticals"},{"issue":"1","key":"5491_CR46","first-page":"vdad111","volume":"5","author":"P Martinez","year":"2023","unstructured":"Martinez P, Nault G, Steiner J, Wempe MF, Pierce A, Brunt B et al (2023) MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model. Neurooncol Adv 5(1):vdad111","journal-title":"Neurooncol Adv"},{"issue":"1","key":"5491_CR47","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","volume":"15","author":"VA Arrieta","year":"2024","unstructured":"Arrieta VA, Gould A, Kim K-S, Habashy KJ, Dmello C, V\u00e1zquez-Cervantes GI et al (2024) Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas. Nat Commun 15(1):4698","journal-title":"Nat Commun"},{"key":"5491_CR48","doi-asserted-by":"publisher","first-page":"102115","DOI":"10.1016\/j.tranon.2024.102115","volume":"49","author":"H Shan","year":"2024","unstructured":"Shan H, Zheng G, Bao S, Yang H, Shrestha UD, Li G et al (2024) Tumor perfusion enhancement by focus ultrasound-induced blood-brain barrier opening to potentiate anti-PD-1 immunotherapy of glioma. Translational Oncol 49:102115","journal-title":"Translational Oncol"},{"issue":"10","key":"5491_CR49","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3390\/pharmaceutics15102479","volume":"15","author":"S Fadera","year":"2023","unstructured":"Fadera S, Chukwu C, Stark AH, Yue Y, Xu L, Chien C-Y et al (2023) Focused Ultrasound-Mediated Delivery of Anti-Programmed Cell Death-Ligand 1 Antibody to the Brain of a Porcine Model. Pharmaceutics 15(10):2479","journal-title":"Pharmaceutics"},{"key":"5491_CR50","doi-asserted-by":"crossref","unstructured":"Filieri S, Miciaccia M, Armenise D, Baldelli OM, Liturri A, Ferorelli S, et al (2025) Can Focused ultrasound overcome the failure of chemotherapy in treating pediatric diffuse intrinsic pontine glioma due to a blood-brain barrier obstacle? Pharmaceuticals (Basel). 18(4)","DOI":"10.3390\/ph18040525"},{"issue":"1","key":"5491_CR51","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12967-024-05096-9","volume":"22","author":"M Tazhibi","year":"2024","unstructured":"Tazhibi M, McQuillan N, Wei HJ, Gallitto M, Bendau E, Webster Carrion A et al (2024) Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma. J Transl Med 22(1):320","journal-title":"J Transl Med"},{"issue":"6371","key":"5491_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371):91\u201397","journal-title":"Science"},{"issue":"6371","key":"5491_CR53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103","journal-title":"Science"},{"key":"5491_CR54","doi-asserted-by":"publisher","first-page":"112881","DOI":"10.1016\/j.intimp.2024.112881","volume":"141","author":"M Zhou","year":"2024","unstructured":"Zhou M, Wu J, Shao Y, Zhang J, Zheng R, Shi Q et al (2024) Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment. Int Immunopharmacol 141:112881","journal-title":"Int Immunopharmacol"},{"key":"5491_CR55","doi-asserted-by":"crossref","unstructured":"Green GBH, Cox-Holmes AN, Potier ACE, Marlow GH, McFarland BC (2024) Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota. Biomedicines. 12(11)","DOI":"10.3390\/biomedicines12112429"},{"issue":"11","key":"5491_CR56","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3390\/biomedicines12112429","volume":"12","author":"GBH Green","year":"2024","unstructured":"Green GBH, Cox-Holmes AN, Potier ACE, Marlow GH, McFarland BC (2024) Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota. Biomedicines 12(11):2429","journal-title":"Biomedicines"},{"issue":"16","key":"5491_CR57","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1002\/cncr.33030","volume":"126","author":"SJ Rotz","year":"2020","unstructured":"Rotz SJ, Dandoy CE (2020) The microbiome in pediatric oncology. Cancer 126(16):3629\u20133637","journal-title":"Cancer"},{"issue":"23","key":"5491_CR58","doi-asserted-by":"publisher","first-page":"15387","DOI":"10.3390\/ijms232315387","volume":"23","author":"D Leardini","year":"2022","unstructured":"Leardini D, Venturelli F, Baccelli F, Cerasi S, Muratore E, Brigidi P et al (2022) Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome. Int J Mol Sci 23(23):15387","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5491_CR59","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","volume":"21","author":"B Geoerger","year":"2020","unstructured":"Geoerger B, Zwaan CM, Marshall LV, Michon J, Bourdeaut F, Casanova M et al (2020) Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1\u20132 study. Lancet Oncol 21(1):134\u2013144","journal-title":"Lancet Oncol"},{"issue":"1","key":"5491_CR60","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s40425-019-0791-x","volume":"7","author":"CS Shemesh","year":"2019","unstructured":"Shemesh CS, Chanu P, Jamsen K, Wada R, Rossato G, Donaldson F et al (2019) Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer 7(1):314","journal-title":"J Immunother Cancer"},{"issue":"10","key":"5491_CR61","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00262-022-03159-8","volume":"71","author":"DM Loeb","year":"2022","unstructured":"Loeb DM, Lee JW, Morgenstern DA, Samson Y, Uyttebroeck A, Lyu CJ et al (2022) Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1\/2 trial. Cancer Immunol Immunother 71(10):2485\u20132495","journal-title":"Cancer Immunol Immunother"},{"issue":"36","key":"5491_CR62","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 39(36):4073\u20134126","journal-title":"J Clin Oncol"},{"issue":"1","key":"5491_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM (2023) Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol 7(1):41","journal-title":"NPJ Precis Oncol"},{"key":"5491_CR64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Farina N, Tomelleri A, Ferrara R, Lazzari C, De Luca G et al (2021) Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med 93:87\u201394","journal-title":"Eur J Intern Med"},{"issue":"9","key":"5491_CR65","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior JO, Peters S, Obeid M (2020) Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol 31(9):1273\u20131275","journal-title":"Ann Oncol"},{"key":"5491_CR66","doi-asserted-by":"crossref","unstructured":"Holmstroem RB, Dahl EK, Helms M, Nielsen HV, Andersen JB, Bjerrum JT, et al (2022) Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. BMJ Open Gastroenterol. 9(1)","DOI":"10.1136\/bmjgast-2022-000989"},{"key":"5491_CR67","doi-asserted-by":"crossref","unstructured":"Fa\u2019ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, et al (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer. 11(6)","DOI":"10.1136\/jitc-2023-006814corr1"},{"issue":"1","key":"5491_CR68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","volume":"36","author":"PF Petit","year":"2025","unstructured":"Petit PF, Daoudlarian D, Latifyan S, Bouchaab H, Mederos N, Doms J et al (2025) Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study. Ann Oncol 36(1):43\u201353","journal-title":"Ann Oncol"},{"issue":"3","key":"5491_CR69","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1002\/hsr2.115","volume":"2","author":"PD Banks","year":"2019","unstructured":"Banks PD, Lasocki A, Lau PKH, Sandhu S, McArthur G, Shackleton M (2019) Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Sci Rep 2(3):e115","journal-title":"Health Sci Rep"},{"key":"5491_CR70","doi-asserted-by":"publisher","first-page":"117556","DOI":"10.1016\/j.jns.2021.117556","volume":"427","author":"A Moore","year":"2021","unstructured":"Moore A, Yust-Katz S, Icht O, Eliyahou R, Gordon N, Cohen AY et al (2021) Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. J Neurol Sci 427:117556","journal-title":"J Neurol Sci"},{"issue":"15","key":"5491_CR71","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16(15):e534\u2013e42","journal-title":"Lancet Oncol"},{"issue":"33","key":"5491_CR72","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M et al (2023) RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 41(33):5187\u20135199","journal-title":"J Clin Oncol"},{"issue":"12","key":"5491_CR73","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.3174\/ajnr.A8396","volume":"45","author":"BM Ellingson","year":"2024","unstructured":"Ellingson BM, Sanvito F, Cloughesy TF, Huang RY, Villanueva-Meyer JE, Pope WB et al (2024) A Neuroradiologist\u2019s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults. AJNR Am J Neuroradiol 45(12):1846\u20131856","journal-title":"AJNR Am J Neuroradiol"},{"key":"5491_CR74","doi-asserted-by":"crossref","unstructured":"Abdulla S, Saada J, Johnson G, Jefferies S, Ajithkumar T. Tumour progression or pseudoprogression?A\u00a0review of post-treatment radiological appearances of glioblastoma. Clinical Radiology. 2015;70(11):1299\u2009\u2013\u2009312.","DOI":"10.1016\/j.crad.2015.06.096"},{"issue":"5","key":"5491_CR75","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2967\/jnumed.122.264859","volume":"64","author":"N Galldiks","year":"2023","unstructured":"Galldiks N, Lohmann P, Fink GR, Langen KJ (2023) Amino Acid PET in Neurooncology. J Nucl Med 64(5):693\u2013700","journal-title":"J Nucl Med"},{"issue":"1","key":"5491_CR76","first-page":"vdad077","volume":"5","author":"K O\u2019Halloran","year":"2023","unstructured":"O\u2019Halloran K, Yellapantula V, Christodoulou E, Ostrow D, Bootwalla M, Ji J et al (2023) Low-pass whole-genome and targeted sequencing of cell-free DNA from cerebrospinal fluid in pediatric patients with central nervous system tumors. Neurooncol Adv 5(1):vdad077","journal-title":"Neurooncol Adv"},{"issue":"12","key":"5491_CR77","first-page":"1363","volume":"20","author":"AM Miller","year":"2022","unstructured":"Miller AM, Karajannis MA (2022) Current Role and Future Potential of CSF ctDNA for the Diagnosis and Clinical Management of Pediatric Central Nervous System Tumors. J Natl Compr Canc Netw 20(12):1363\u20131369","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"5491_CR78","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.3390\/cancers15133532","volume":"15","author":"M Chicard","year":"2023","unstructured":"Chicard M, Iddir Y, Masliah Planchon J, Combaret V, Attignon V, Saint-Charles A et al (2023) Cell-Free DNA Extracted from CSF for the Molecular Diagnosis of Pediatric Embryonal Brain Tumors. Cancers 15(13):3532","journal-title":"Cancers"},{"issue":"1","key":"5491_CR79","doi-asserted-by":"publisher","first-page":"101918","DOI":"10.1016\/j.xcrm.2024.101918","volume":"6","author":"N Erez","year":"2025","unstructured":"Erez N, Furth N, Fedyuk V, Wadden J, Aittaleb R, Adam T et al (2025) Single-molecule systems for the detection and monitoring of plasma-circulating nucleosomes and oncoproteins in diffuse midline glioma. Cell Rep Med 6(1):101918","journal-title":"Cell Rep Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05491-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05491-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05491-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:06:33Z","timestamp":1776074793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05491-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5491"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05491-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Portions of the text in this manuscript were refined with the assistance of ChatGPT (GPT-4, OpenAI, version 2025-10). The tool was used exclusively to improve the clarity, grammar, and readability of language originally written by the authors and to help structure certain sections for improved flow. It was not used to generate original scientific content, data, analysis, images, or conclusions, and all outputs were critically reviewed, verified, and edited by the authors to ensure accuracy and integrity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of generative AI"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}